ON SALE: TICKETS FOR THE HIGHLY ANTICIPATED 17th ANNUAL RITZ-CARLTON CAYMAN COOKOUT AVAILABLE OCTOBER 1

Award-winning Chefs Eric Ripert, José Andrés, Emeril Lagasse, Stephanie Izard Carla Hall and more Gather for this Premier Event, January 14 19, 2026 as the Legendary Resort Celebrates its 20 th Anniversary

High-Res Images of The Ritz-Carlton, Grand Cayman's 16th Annual Cayman Cookout Here

GRAND CAYMAN , Cayman Islands , Sept. 29, 2025 /PRNewswire/ -- The first and only Forbes Triple Five-Star hotel in the Caribbean The Ritz-Carlton, Grand Cayman – announced that tickets will officially go on sale for the 17th annual Ritz-Carlton Cayman Cookout on Wednesday, October 1 . The premier culinary event will take place January 14-19, 2026 , at the iconic luxury resort, which is also celebrating its 20 th anniversary.

Featuring more than 60 immersive cooking demonstrations, expert-led tastings and transformative excursions, the exclusive Caribbean experience will be headlined by a stacked roster of award-winning talent including Eric Ripert , José Andrés, Andrew Zimmern , Stephanie Izard , and Carla Hall among many others. Individual event tickets and overnight accommodations are available for purchase at caymancookout.com .

Cayman Cookout 2026 Overnight Offer
Guests looking to further elevate their experience with unrivaled access can book the Cayman Cookout Room Package. Starting at $2,600 USD (exclusive of applicable taxes and fees) per night for two guests (five-night minimum stay January 14-19, 2026 ), this one-of-a-kind offer includes luxury accommodations, daily gourmet surprises delivered in-room and exclusive access to signature events including An Epicurean Eve presented by Forbes Travel Guide, Marriott Bonvoy ® Credit Card by Chase presents Barefoot BBQ, a Rum & Robusto poolside celebration and more. To reserve the overnight package, please contact the resort by email at caymanreservations@ritzcarlton.com or dial +1 (345) 815-6300.

"As we celebrate the 20th anniversary of The Ritz-Carlton, Grand Cayman , this year's Cayman Cookout takes on even greater meaning," said Marc Langevin , General Manager of The Ritz-Carlton, Grand Cayman . "Each year we strive to bring a more dynamic experience for our guests, and this year they can look forward to a week of unforgettable culinary moments and bold experiences that honor both the two-decade legacy of our resort and the spirit of Grand Cayman ."

This year brings new themes and events including a health-forward panel hosted by Chef Andrew Zimmern with Gavin Kaysen and Gregory Gourdet , plus Haitian and Chinese-inspired demonstrations from Gourdet and Ming Tsai .

"For the last 17 years, Cayman Cookout has transformed Grand Cayman into a stage for unmatched culinary experiences," said Chef Eric Ripert . "From the approachable atmosphere of the After Glow poolside soirée to the debut of our new jazz dinner - every event is designed to create lasting memories found only at Cookout. These experiences highlight not only world-class cuisine but also the vibrant spirit of this treasured island, which is the essence of what makes this annual event so exceptional."

The culinary adventure is revered for the genuine camaraderie among the headlining chefs who deliver illustrious events throughout the action-packed week; Event highlights for this year include:

  • An Epicurean Eve: The Grand Opening Reception presented by Forbes Travel Guide: A kickoff to an unforgettable weekend, the Grand Opening Reception at Cayman Cookout will also commemorate the esteemed resort's 20 th anniversary this year. This lively evening brings together the world-class chefs of the festival for a celebration of flavor, community, and connection. Guests will explore chef-led food stations featuring signature creations, paired with outstanding wines.

  • Eric Ripert – Wheels Up Journey to GoldenEye: Join Chef Eric Ripert presents an unforgettable private jet experience to the legendary GoldenEye resort in Jamaica , presented by Wheels Up. Attendees will soar over breathtaking landscapes while enroute to the iconic retreat that once inspired James Bond . Upon arrival, they will enjoy a thoughtfully prepared lunch featuring the best of local ingredients, followed by time to explore the storied property and its lush surroundings.

  • José Andrés - Longer Tables Live: José Andrés at Cayman Cookout: José Andrés returns this year to host a live recording of his podcast, Longer Tables , at the Cayman Cookout. Each episode explores the impact of food on society and its role in fostering connections. A special guest for this event will be revealed closer to the event.

  • Christophe Bellanca – The Essential French Table: With a career shaped by legendary chefs and Michelin-starred kitchens, Chef Bellanca brings refined technique, thoughtful composition, and deep respect for ingredients to every dish. In this intimate demo that will take place in the Cayman Islands Ballroom, he will share the foundations that define his cooking—tradition, elegance, and mentorship – offering a masterclass in what makes French cuisine essential to the culinary world.

  • Elena Reygades – Mexican Traditions Reimagined: Known for her thoughtful, ingredient-driven cuisine at Rosetta and Panadería Rosetta in Mexico City , Chef Reygadas brings her philosophy to life through inventive dishes that honor Mexico's biodiversity and culinary heritage. With a focus on sustainability, women's leadership, and food as cultural expression, this demo is an invitation to explore how tradition and innovation can beautifully coexist on the plate.

  • Stephanie Izard – Duck, Duck, Cayman: Award-winning chef and television personality Stephanie Izard brings her dynamic Chicago style to the shores of the Cayman Islands for a one-night-only dinner experience. Drawing inspiration from her beloved restaurants Girl & the Goat, Cabra, and beyond, this beachfront evening displays her bold, globally inspired dishes designed for sharing. Expect a lively, unforgettable night filled with creativity, great food, and the spirit of culinary adventure.

  • Gavin Kaysen – Modern Midwest: Join Chef Gavin Kaysen for this culinary demonstration that explores how tradition, innovation, and a deep sense of place come together on the plate. Known for shaping the Twin Cities dining scene and mentoring the next generation of chefs, Chef Kaysen offers insight into the flavors, techniques, and philosophy behind his acclaimed restaurants. This is a rare opportunity to learn from one of the leading voices in contemporary American cuisine.

  • Ripert & Pétanque Presented by Robb Report: Join Chef Eric Ripert and friends for a spirited match of pétanque at Andiamo Circolo Sportivo, a beloved tradition of Cayman Cookout! This friendly competition brings together world-class chefs, passionate guests, and playful rivalries. As the game unfolds, savor an array of delicious bites thoughtfully prepared featuring fresh, vibrant flavors that reflect the island's culinary spirit. Sip on crisp, refreshing rosé wines from Domaines Ott, expertly selected to enhance the experience and keep the good vibes flowing. Whether you are a seasoned pétanque player or a curious spectator, this event offers a perfect blend of camaraderie, coastal charm, and culinary delight in true Cookout fashion.

  • Meals on Wheels: The Meals on Wheels event brings together headlining chefs from Cayman Cookout, alongside media and VIPs, to prepare boxed meals for Caymanians in need. Participants will work collaboratively to assemble the meals and, afterward, Meals on Wheels will manage the delivery, with several chefs also taking the opportunity to join in support of the community.

  • The Grand Finale Dinner at Blue by Eric Ripert : Commemorate a momentous five days and a milestone anniversary by honoring two decades of the resort's legacy and 17 unforgettable years of The Ritz-Carlton Cayman Cookout. This decadent multi-course dinner brings together world-renowned chefs, each contributing their signature style to a seamless and spectacular culinary experience. Paired with exceptional wines and set in a refined, celebratory atmosphere, this evening is a tribute to the past, present, and future of one of the Caribbean's most iconic culinary traditions.

Individual ticket sales for Cayman Cookout 2026 will be available for purchase on the festival's website . For further information and bookings, please visit https://www.ritzcarlton.com/en/hotels/caribbean/grand-cayman .

About The Ritz-Carlton, Grand Cayman
The Ritz-Carlton, Grand Cayman , the Caribbean's first and only resort to earn the coveted Triple Five-Star designation from Forbes Travel Guide, spans 144 meticulously manicured acres from the tranquil North Sound to the iconic white sands of Seven Mile Beach. Following a comprehensive renovation in 2021, the resort features 369 elegantly appointed guest rooms and suites, reimagined by the acclaimed Champalimaud Design. Guests can indulge in six diverse dining venues, including Blue by Eric Ripert , the Caribbean's sole Forbes Travel Guide Five-Star restaurant, which recently underwent a stunning transformation, and the newly revitalized Andiamo Circolo Sportivo, offering an updated and vibrant space for casual dining and recreational activities. The Five-Star Ritz-Carlton Spa provides a bespoke collection of revitalizing treatments, while golf enthusiasts can enjoy a Greg Norman -designed nine-hole course and a state-of-the-art indoor simulator equipped with Trackman technology. For events, the property boasts the island's largest ballroom and an interactive culinary studio. Family programming through Jean-Michel Cousteau's Ambassadors of the Environment invites guests of all ages to explore Cayman's natural wonders, with additional recreational amenities including the Starfish Cay Water Park, TitanTrax ® tennis courts, pickleball and basketball courts, as well as an indoor game room. Unparalleled accommodations include the Seven South Penthouse boasting more than 8,000 square-feet of indoor and outdoor living space, breathtaking Caribbean Sea views, elegant interiors, dedicated concierge service and more. Each year, the resort and Chef Eric Ripert host the renowned Ritz-Carlton Cayman Cookout, bringing together some of the world's most celebrated chefs and epicurean enthusiasts for an unforgettable culinary experience.
For more information about The Ritz-Carlton, Grand Cayman , please visit www.ritzcarlton.com/grandcayman or dial +1 (345) 943-9000.

About The Ritz-Carlton Hotel Company, LLC
Delivering the Gold Standard in service in coveted destinations around the world, The Ritz-Carlton Hotel Company, LLC currently operates more than 120 hotels in over 35 countries and territories. From iconic urban destinations to stretches of paradise in untouched corners of the earth, The Ritz-Carlton offers the opportunity for true discovery and transformative escapes that stay with guests long after they depart. Committed to thoughtful innovation, The Ritz-Carlton encompasses two groundbreaking brand extensions, Ritz-Carlton Reserve and The Ritz-Carlton Yacht Collection. Ritz-Carlton Reserve is a collection of rare estates set apart from the world, where personalized care and cultural immersion are paramount. The Ritz-Carlton Yacht Collection translates the brand's legendary service and hospitality for sea, reimagining the ultra-luxury cruising category. For more information or reservations, visit the company website at www.ritzcarlton.com , for the latest company updates, visit news.marriott.com and to join the live conversation, use #RCMemories and follow along on Facebook , X , and Instagram . The Ritz-Carlton Hotel Company, L.L.C. is a wholly owned subsidiary of Marriott International, Inc. (NASDAQ:MAR). The Ritz-Carlton is proud to participate in Marriott Bonvoy ® , the global travel program from Marriott International. The program offers members an extraordinary portfolio of global brands, exclusive experiences on Marriott Bonvoy Moments and unparalleled benefits including complimentary nights and Elite status recognition. To enroll for free or for more information about the program, visit marriottbonvoy.com . The Ritz-Carlton is committed to supporting the destinations where it operates through Community Footprints, the company's social and environmental responsibility program.

About Marriott Bonvoy ®
Marriott Bonvoy's extraordinary portfolio offers renowned hospitality in the most memorable destinations in the world, with more than 30 brands that are tailored to every type of journey. From The Ritz-Carlton and St. Regis to W Hotels and more, Marriott Bonvoy has more luxury offerings than any other travel program. Members can earn points for stays at hotels and resorts, including all-inclusive resorts and premium home rentals, and through everyday purchases with co-branded credit cards. Members can redeem their points for experiences including future stays, Marriott Bonvoy Moments , or through partners for luxurious products from Marriott Bonvoy Boutiques ® . To enroll for free or for more information about Marriott Bonvoy, visit marriottbonvoy.com .

About Chase
Chase is the U.S. consumer and commercial banking business of JPMorgan Chase & Co. (NYSE: JPM), a leading financial services firm based in the United States with assets of $4.1 trillion and operations worldwide. Chase serves more than 82 million consumers and 6.4 million small businesses, with a broad range of financial services, including personal banking, credit cards, mortgages, auto financing, investment advice, small business loans and payment processing. Customers can choose how and where they want to bank: More than 4,800 branches in 48 states and the District of Columbia , more than 15,000 ATMs, mobile, online and by phone. For more information, go to chase.com

Cision View original content to download multimedia: https://www.prnewswire.com/news-releases/on-sale-tickets-for-the-highly-anticipated-17th-annual-ritz-carlton-cayman-cookout-available-october-1-302568603.html

SOURCE The Ritz-Carlton, Grand Cayman

News Provided by PR Newswire via QuoteMedia

JPM
The Conversation (0)
Sirona Biochem CEO Quarterly Update

Sirona Biochem CEO Quarterly Update

Sirona Biochem Corp . (TSX-V: SBM) (FSE: ZSB) (OTC: SRBCF) (" Sirona ") is pleased to provide the following update to shareholders.

Dear shareholders,

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
rodan and fields animal testing

/R E P E A T -- Sirona Biochem CEO Quarterly Update Q2 2021/

Sirona Biochem Corp . (TSXV: SBM) (FSE: ZSB) (OTC: SRBCF) (" Sirona ") is pleased to provide the following update to shareholders.

Dear shareholders,

News Provided by Canada Newswire via QuoteMedia

Keep reading...Show less
Sirona Biochem CEO Quarterly Update Q2 2021

Sirona Biochem CEO Quarterly Update Q2 2021

Sirona Biochem Corp . (TSXV: SBM) (FSE: ZSB) (OTC: SRBCF) (" Sirona ") is pleased to provide the following update to shareholders.

Dear shareholders,

We are providing this update along with our quarterly results. We will continue to provide an update each quarter and will update our milestone list at that time as well.

It is important to appreciate that each of our projects relies on partners. Whether this is the manufacturing and supply organizations, the contract research groups that run our studies, or the potential commercial partners completing their own studies and reviews as part of due diligence. Our prospective global partners conduct due diligence that is extremely detailed and often takes longer than anticipated. Each of these partners has their own unique organizational structures and schedules and they are often met with challenges that cause delays. In the best of times this is the case, but in the past year we have dealt with far more. Sirona has internally managed recent global challenges with little to no adversity, but larger organization have been less successful.

We take this opportunity to apologize to our investment community for our mistakes when it came to estimating some of our project timelines and we will strive to do better going forward. We assure you that our projects have not been discontinued, that our science team is actively working on contributions to partner due diligence activities as well as expanding our pipeline with new IP, and that our business teams are continuously meeting with large global corporations to discuss ongoing and new partnerships.

The individual project updates are as follows:

TFC-1067

North America
We are very pleased that TFC-1067, our active ingredient for dark spots on or hyperpigmentation of the skin, has now been commercialized.

On March 10, 2021 , we announced that Rodan + Fields (R+F) had successfully launched TFC-1067 as the active ingredient in the new REVERSE Targeted Dark Spot Corrector . We are extremely proud to have contributed to the first commercialization of the technology developed by our award-winning CSO Dr. Geraldine Deliencourt-Godefroy. This launch not only validated our technology but has also opened the door for further collaborations as global players have increased confidence to add TFC-1067 to their product portfolios.

Commercial products that include TFC-1067 will have different levels of efficacy depending on the concentration of our active and the formula (cream, serum, etc) developed by the commercial partner. In addition, all spot correctors take time to be effective and the visible results steadily become more apparent over time. Even the industry standard, hydroquinone, takes weeks to show an effect despite achieving results partially through toxicity. TFC-1067 blocks the formation of new pigment and existing pigment must degrade over time. Our science team is convinced we developed an excellent formulation in our clinical trials and remain highly confident in our product. Participants in our second double blind clinical trial support this conclusion. This trial demonstrated, successfully, the powerful effect of our TFC-1067 formulas with 100% of participants seeing an improved complexion and concluding they would buy this product.

With great results confirmed by consumers, we have again increased manufacturing in China and have currently arranged to secure an inventory of product that will be able to meet the growing demand. Our manufacturing partner, WuXi AppTec has provided dedicated resources for our compound and can produce significant quantities with little turnaround time. As we continue to scale, product supply will not be an issue.

Our second clinical trial for TFC-1067 completed in Feb 2021 . At this time, our pharmaceutical partner continues their due diligence and will do so for a previously agreed upon time. A successful transaction with the trial partner is management's goal as it would be transformational for Sirona. While many global pharmaceutical and dermatological companies continue to approach Sirona with interest in TFC-1067, we are obligated to delay in-depth discussions involving the clinical trial results until our partner has completed analysis of the clinical results and determined their next steps. Due diligence by global leaders takes time no matter how confident they are in the ultimate commercial success since they follow meticulous procedures with large teams. We observed this with Rodan + Fields as great care is required to maintain the brand excellence.

Our VP of Operations, Michelle Seltenrich , attended BIO from June 14 th to June 18 th and met with 12 organizations from the following countries/regions: Japan , Korea, China , USA , Canada , Europe to discuss various programs. Each of these meetings was pursued by the larger organization and will be followed up with data exchange.

We will be successful in further commercialization of TFC-1067 globally.

Asia
We continue to implement our Asia strategy and are in discussions with a China -based company which has established cosmetic development excellence as discussed in our last news update. An evolving and varied regulatory landscape for new compounds throughout Asia has created challenges. Each country in Asia has enormous commercial potential and we do not want to miss any of these opportunities. As such, we are advancing another compound, TFC-1394, from our patented library of skin lighteners to the same level as TFC-1067. This will occur over the next 12-18 months and ensure that country regulatory testing, if required, can be performed by other companies. We will then be able to launch in every country where a market exists in this $20 Billion USD industry. Our scientists have outlined a development path based on the expertise we have developed which is both efficient and affordable. It will occur in parallel to commercialization of TFC-1067 and not delay current plans. The value of our portfolio, which includes TFC-1067 and TFC-1394, will grow as they advance towards becoming a new industry gold standard as both safe and effective compounds. Having a regional partner is an important component in successful achieving our goals in a timely manner.

Tinyi Trading Company remains on board to be a distribution partner, however, with current discussions ongoing, we wait to see if the new partner in China seeks exclusive distribution. Ultimately, we will decide in the best interests of our company and shareholders.

TFC-039

Human Diabetes
Our partner, Wanbang Biopharmaceuticals, has informed us that our compound for type 2 diabetes (TFC-039) has completed their Phase I studies and the data is in the analysis phase. We expected to hear the results of this before the Chinese New Year in early February, however, they have experienced delays in the data analysis. We are now waiting and pushing to have a final report of these results and will update shareholders as soon as material information is available for release.

Animal Health
TFC-039 for animal health continues to progress. We are now in contact with four international companies on this project. Two additional global animal health companies reached out to our team, and we have exchanged data that they are currently reviewing.

We are evaluating the best way forward and still anticipate having both a manufacturing and a commercialization partner for the animal health product. We have established assistance from Wanbang in this regard and have their full commitment.

Other Indications
The team at TFChem is investigating further indications for TFC-039 and have identified the target diseases. Once the patents have been established, we will provide more information. Premature release of information can prevent the ability to patent a technology and our company relies on IP as assets, so we ask for patience in this regard.

Anti-Aging

Our anti-aging library has been completed and a lead compound has been chosen. These actives target multiple pathways in the aging process in different layers of the skin, which creates a very innovative treatment against skin aging and wrinkles. However, the complexity of this means that the compound will require multiple and extensive evaluations with different contract research organizations to identify a mechanism of action. We are now planning and executing the studies required for clinical testing. Several studies in this regard, including safety studies have started and we will announce initial results by Q4 of the calendar year. New indications for these compounds have been discovered through the evaluation process and has expanded the potential target commercial opportunities and will lead to another specific patent in 2022.

In our last update, we stated that the project was introduced to several companies at BIO JPM. The team in France put together a very detailed information package for this project, which contains the preclinical studies and results. This was distributed to several companies at the end of May and again following BIO in June. Discussions with partners remain preliminary at this stage.

Antiviral

Our antiviral compounds are in the chemistry phase, and we will update as progress is made. Several actives have been already prepared and we are building our portfolio for evaluation in different assays. There remains a critical unmet need for drugs that can halt the extreme progression of some viruses. We have identified compound structures that fit our platform and have a clear  path of development.

Financing

Sirona's last private placement financing was 2 years ago, a similar financing is not planned. Management has a strategy on how to move forward including non-dilutive sources currently being explored.

Despite our limited recent news flow, we are very excited with our progress towards future partnerships and licencing deals. Commercialization of the pipeline is becoming a growing reality which will ultimately reward our shareholders.

Dr. Howard Verrico, CEO

About Sirona Biochem Corp.

Sirona Biochem is a cosmetic ingredient and drug discovery company with a proprietary platform technology. Sirona specializes in stabilizing carbohydrate molecules with the goal of improving efficacy and safety. New compounds are patented for maximum revenue potential.

Sirona's compounds are licensed to leading companies around the world in return for licensing fees, milestone fees and ongoing royalty payments. Sirona's laboratory, TFChem, is in France and is the recipient of multiple French national scientific awards and European Union and French government grants. For more information, please visit www.sironabiochem.com .

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

---------------------------------------------

Sirona Biochem cautions you that statements included in this press release that are not a description of historical facts may be forward-looking statements. Forward-looking statements are only predictions based upon current expectations and involve known and unknown risks and uncertainties. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of release of the relevant information, unless explicitly stated otherwise.  Actual results, performance or achievement could differ materially from those expressed in, or implied by, Sirona Biochem's forward-looking statements due to the risks and uncertainties inherent in Sirona Biochem's business including, without limitation, statements about: the progress and timing of its clinical trials; difficulties or delays in development, testing, obtaining regulatory approval, producing and marketing its products; unexpected adverse side effects or inadequate therapeutic efficacy of its products that could delay or prevent product development or commercialization; the scope and validity of patent protection for its products; competition from other pharmaceutical or biotechnology companies; and its ability to obtain additional financing to support its operations. Sirona Biochem does not assume any obligation to update any forward-looking statements except as required by law.

SOURCE Sirona Biochem Corp.

Cision View original content to download multimedia: https://www.newswire.ca/en/releases/archive/June2021/30/c1507.html

News Provided by Canada Newswire via QuoteMedia

Keep reading...Show less
/R E P E A T -- Sirona Biochem CEO Quarterly Update Q1 2021/

/R E P E A T -- Sirona Biochem CEO Quarterly Update Q1 2021/

Sirona Biochem Corp . (TSXV: SBM) (FSE: ZSB) (OTC: SRBCF) (" Sirona ") is pleased to provide the following update to shareholders.

We continue to make substantial progress with core deliverables.

TFC-1067

Rodan + Fields (R+F) is completing the final stages in preparation to launch one of their newest skin care products incorporating TFC-1067. The dates are tightly guarded at this time and shareholders will be updated as soon as we are able to do so. We can report that everything is still progressing on schedule. As this will be our first project to reach commercial sales, we are looking forward to a successful launch.

Manufacturing of commercial quality TFC-1067 is ongoing in both China and France and shipments have been completed from both countries to the USA . As is the case with most new manufacturing, we continue to invest in optimizing the process. The development of an optimal production is an initial investment and a necessary condition to ensure we can sustainably serve a growing demand.

Our second clinical trial for TFC-1067, utilizing a higher dose, has been successfully completed and preliminary results have been received from Dermscan. We expect the final report within 4 weeks at which time we will review the results with our pharmaceutical partner ( see news Oct 2020 ). We anticipate being able to release a portion of the results that are independent of our partner after a period of due diligence.

Several multinational companies have approached Sirona with interest in TFC-1067. Once the first product is available for purchase and we can release the latest data, we anticipate that number to grow. The data package now contains many in vitro studies, clinical safety data, two clinical trials and manufacturing. Additionally, we have a partner who independently tested the product providing further support for its performance.

After completing our due diligence, we made the decision not to  pursue an agreement with HuaxiPharm. They have experienced internal challenges and delays and we do not feel their goals align with Sirona at this time. We have been working on developing a relationship with another company that can manage all aspects of commercialization of TFC-1067 in China . Our board and senior team are in regular discussion with this company on moving forward with an agreement. Extensive due diligence has already occurred.

TFC-039

TFC-039 for a type 2 diabetes pharmaceutical has completed another major phase in development and material information is pending.

TFC-039 for animal health continues to progress. We are in discussions with two international companies on this project and as such it has taken more time than expected to coordinate. Sirona and its consultants have structured and negotiated this unique partnership. We have closed binding terms on one side of this deal with the partner and we anticipate the other partner closing soon. Until such time that both partners have agreed to all terms, the details must remain confidential.

In addition, the team at TFChem are currently investigating further indications for TFC-039.

Anti-Aging

Our team has recently completed further studies for our anti-aging project to analyze our library of compounds and determine a lead. While we had previously done studies on some of these compounds, the lab was successful in developing further compounds for the library which we believe may have additional potential. These compounds must be patented and to do so, it is a requirement to  fulfill a set of in-vitro studies. The studies are now complete, and we can begin the next steps of preparing a lead for further investigative studies in safety prior to the clinical trial. The project was introduced to several companies at BIO JPM ( https://www.bio.org/events/bio-partnering-jpm ) and we are developing the information package to share with them. We also anticipate further discussions with our current partners about this project.

Antiviral

With recent developments in other projects as well as the lab's dedication to scale-up and managing the clinical trials of this project, the antiviral project remains less of a priority at the moment, but very much on the agenda for 2021 and 2022. We will update as progress is made.

Sirona continues to thrive in a world which has become increasingly virtual and has been conducting business daily on four continents. With a well-seasoned and experienced team, including multiple locally based consultants, travel has become unnecessary to maintain our progress. We will continue to support and grow our pipeline technology developed by our dedicated team of TFChem scientists based in Rouen, France .

We also continue to focus our efforts to create significant value for our shareholders. We realize that some investors had hoped for more progress. However, once again, we are moving forward and we are very confident that we will reach further significant milestones and continue to develop Sirona as a commercially successful company.

Dr. Howard Verrico, CEO

About Sirona Biochem Corp.

Sirona Biochem is a cosmetic ingredient and drug discovery company with a proprietary platform technology. Sirona specializes in stabilizing carbohydrate molecules with the goal of improving efficacy and safety. New compounds are patented for maximum revenue potential.

Sirona's compounds are licensed to leading companies around the world in return for licensing fees, milestone fees and ongoing royalty payments. Sirona's laboratory, TFChem, is located in France and is the recipient of multiple French national scientific awards and European Union and French government grants. For more information, please visit www.sironabiochem.com .

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Sirona Biochem cautions you that statements included in this press release that are not a description of historical facts may be forward-looking statements. Forward-looking statements are only predictions based upon current expectations and involve known and unknown risks and uncertainties. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of release of the relevant information, unless explicitly stated otherwise.  Actual results, performance or achievement could differ materially from those expressed in, or implied by, Sirona Biochem's forward-looking statements due to the risks and uncertainties inherent in Sirona Biochem's business including, without limitation, statements about: the progress and timing of its clinical trials; difficulties or delays in development, testing, obtaining regulatory approval, producing and marketing its products; unexpected adverse side effects or inadequate therapeutic efficacy of its products that could delay or prevent product development or commercialization; the scope and validity of patent protection for its products; competition from other pharmaceutical or biotechnology companies; and its ability to obtain additional financing to support its operations. Sirona Biochem does not assume any obligation to update any forward-looking statements except as required by law.

SOURCE Sirona Biochem Corp.

Cision View original content to download multimedia: https://www.newswire.ca/en/releases/archive/February2021/24/c3041.html

News Provided by Canada Newswire via QuoteMedia

Keep reading...Show less
Sirona Biochem CEO Quarterly Update Q1 2021

Sirona Biochem CEO Quarterly Update Q1 2021

Sirona Biochem Corp . (TSXV: SBM) (FSE: ZSB) (OTC: SRBCF) (" Sirona ") is pleased to provide the following update to shareholders.

We continue to make substantial progress with core deliverables.

TFC-1067

Rodan + Fields (R+F) is completing the final stages in preparation to launch one of their newest skin care products incorporating TFC-1067. The dates are tightly guarded at this time and shareholders will be updated as soon as we are able to do so. We can report that everything is still progressing on schedule. As this will be our first project to reach commercial sales, we are looking forward to a successful launch.

Manufacturing of commercial quality TFC-1067 is ongoing in both China and France and shipments have been completed from both countries to the USA . As is the case with most new manufacturing, we continue to invest in optimizing the process. The development of an optimal production is an initial investment and a necessary condition to ensure we can sustainably serve a growing demand.

Our second clinical trial for TFC-1067, utilizing a higher dose, has been successfully completed and preliminary results have been received from Dermscan. We expect the final report within 4 weeks at which time we will review the results with our pharmaceutical partner ( see news Oct 2020 ). We anticipate being able to release a portion of the results that are independent of our partner after a period of due diligence.

Several multinational companies have approached Sirona with interest in TFC-1067. Once the first product is available for purchase and we can release the latest data, we anticipate that number to grow. The data package now contains many in vitro studies, clinical safety data, two clinical trials and manufacturing. Additionally, we have a partner who independently tested the product providing further support for its performance.

After completing our due diligence, we made the decision not to  pursue an agreement with HuaxiPharm. They have experienced internal challenges and delays and we do not feel their goals align with Sirona at this time. We have been working on developing a relationship with another company that can manage all aspects of commercialization of TFC-1067 in China . Our board and senior team are in regular discussion with this company on moving forward with an agreement. Extensive due diligence has already occurred.

TFC-039

TFC-039 for a type 2 diabetes pharmaceutical has completed another major phase in development and material information is pending.

TFC-039 for animal health continues to progress. We are in discussions with two international companies on this project and as such it has taken more time than expected to coordinate. Sirona and its consultants have structured and negotiated this unique partnership. We have closed binding terms on one side of this deal with the partner and we anticipate the other partner closing soon. Until such time that both partners have agreed to all terms, the details must remain confidential.

In addition, the team at TFChem are currently investigating further indications for TFC-039.

Anti-Aging

Our team has recently completed further studies for our anti-aging project to analyze our library of compounds and determine a lead. While we had previously done studies on some of these compounds, the lab was successful in developing further compounds for the library which we believe may have additional potential. These compounds must be patented and to do so, it is a requirement to  fulfill a set of in-vitro studies. The studies are now complete, and we can begin the next steps of preparing a lead for further investigative studies in safety prior to the clinical trial. The project was introduced to several companies at BIO JPM ( https://www.bio.org/events/bio-partnering-jpm ) and we are developing the information package to share with them. We also anticipate further discussions with our current partners about this project.

Antiviral

With recent developments in other projects as well as the lab's dedication to scale-up and managing the clinical trials of this project, the antiviral project remains less of a priority at the moment, but very much on the agenda for 2021 and 2022. We will update as progress is made.

Sirona continues to thrive in a world which has become increasingly virtual and has been conducting business daily on four continents. With a well-seasoned and experienced team, including multiple locally based consultants, travel has become unnecessary to maintain our progress. We will continue to support and grow our pipeline technology developed by our dedicated team of TFChem scientists based in Rouen, France .

We also continue to focus our efforts to create significant value for our shareholders. We realize that some investors had hoped for more progress. However, once again, we are moving forward and we are very confident that we will reach further significant milestones and continue to develop Sirona as a commercially successful company.

Dr. Howard Verrico, CEO

About Sirona Biochem Corp.

Sirona Biochem is a cosmetic ingredient and drug discovery company with a proprietary platform technology. Sirona specializes in stabilizing carbohydrate molecules with the goal of improving efficacy and safety. New compounds are patented for maximum revenue potential.

Sirona's compounds are licensed to leading companies around the world in return for licensing fees, milestone fees and ongoing royalty payments. Sirona's laboratory, TFChem, is located in France and is the recipient of multiple French national scientific awards and European Union and French government grants. For more information, please visit www.sironabiochem.com .

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Sirona Biochem cautions you that statements included in this press release that are not a description of historical facts may be forward-looking statements. Forward-looking statements are only predictions based upon current expectations and involve known and unknown risks and uncertainties. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of release of the relevant information, unless explicitly stated otherwise.  Actual results, performance or achievement could differ materially from those expressed in, or implied by, Sirona Biochem's forward-looking statements due to the risks and uncertainties inherent in Sirona Biochem's business including, without limitation, statements about: the progress and timing of its clinical trials; difficulties or delays in development, testing, obtaining regulatory approval, producing and marketing its products; unexpected adverse side effects or inadequate therapeutic efficacy of its products that could delay or prevent product development or commercialization; the scope and validity of patent protection for its products; competition from other pharmaceutical or biotechnology companies; and its ability to obtain additional financing to support its operations. Sirona Biochem does not assume any obligation to update any forward-looking statements except as required by law.

SOURCE Sirona Biochem Corp.

Cision View original content to download multimedia: https://www.newswire.ca/en/releases/archive/February2021/24/c7526.html

News Provided by Canada Newswire via QuoteMedia

Keep reading...Show less
Justin Grossbard, co-founder of CompareForexBrokers.

Managing Wealth Across Borders: Q&A with CompareForexBrokers’ Justin Grossbard

Navigating international money transfers can be costly and complex, with hidden fees and poor exchange rates often eroding returns. To shed light on how individuals and businesses can better manage these transactions, the Investing News Network sat down for a Q&A with Justin Grossbard, co-founder of CompareForexBrokers, who shared strategies for cross-border transfers and smart investing.

Keep reading...Show less
Text saying "decentralized finance" with colorful digital chart backdrop.

A Guide to DeFi: Understanding Decentralized Finance

Decentralized finance (DeFi) is a revolutionary shift in the financial landscape, offering a blockchain-based system that facilitates transactions without relying on traditional intermediaries like banks or brokerages.

While the DeFi sector experienced a challenging period through 2022 and early 2023, the latter half of 2023 saw a significant resurgence. This growth was largely fueled by the anticipation and eventual approval of spot crypto exchange-traded funds (ETFs) in the US, signaling a pivotal moment for digital assets.

These moves were a major step toward blending digital assets with traditional financial products, a transition that has been further driven by the increasing maturation and institutionalization of the crypto ecosystem.

Keep reading...Show less
Contactless payment with blue card on smartphone displaying €18.00.

Digital Finance Fuels Record Savings Growth in Developing Nations: World Bank

Formal saving in developing economies surged to its highest level in more than a decade in 2024, powered largely by the widespread use of mobile phones and digital financial tools, the World Bank said in its new Global Findex 2025 report.

For the first time, 40 percent of adults in low- and middle-income countries reported saving money through a bank or other financial institution—marking a 16-percentage-point increase since 2021 and the sharpest three-year rise since the Findex survey began.

Keep reading...Show less
Blue cubes with illuminated edges and symbols, arranged in a geometric pattern.

Fintech Firm Velocity Raises US$10 Million for Enterprise Stablecoin Infrastructure

In what is believed to be the largest European pre-seed funding round of the year, UK fintech startup Velocity has emerged with US$10 million in early backing to develop a stablecoin infrastructure platform.

The initiative is aimed squarely at large enterprises grappling with outdated cross-border financial systems.

The round, led by US-based Activant Capital, brings together global investors and fintech insiders, underscoring growing confidence in stablecoins as a practical tool for enterprise-grade settlement — not just crypto speculation.

Keep reading...Show less
Equity Story Group Limited

Strategic Investor Acquires 11.6% of Equity Story and New Director Appointment

The Board of Equity Story Group Ltd (ASX: EǪS) ("Equity Story" or "the Company") is pleased to announce that Capital Haus Pty Ltd has acquired an 11.6% strategic stake in the Company at 2.6 cents per share, aligning with the last traded price on the ASX.

Keep reading...Show less
Man holding iPad with fintech imagery above.

Top 5 NASDAQ Fintech Stocks (Updated January 2025)

Fintech, or financial technology, has become an integral part of everyday life, and many US fintech stocks are seeing success.

Firms like Boston Consulting Group and Silicon Valley Bank are projecting growth in the market, and since the fintech umbrella covers such a wide range of companies, diverse businesses can profit as the industry develops.

Read on for a look at the NASDAQ's best-performing fintech stocks of the year. Data was gathered using TradingView's stock screener on January 8, 2025, and companies with market caps of at least US$50 million were considered.

Keep reading...Show less

Latest Press Releases

Related News